EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-08
DOI
10.1038/s41571-020-00447-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
- (2020) Daniel J. Brat et al. ACTA NEUROPATHOLOGICA
- Prediagnostic symptoms and signs of adult glioma: the patients’ view
- (2020) Marthe C. M. Peeters et al. JOURNAL OF NEURO-ONCOLOGY
- Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma
- (2020) William G Breen et al. NEURO-ONCOLOGY
- Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma
- (2020) Antje Wick et al. NEURO-ONCOLOGY
- Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma
- (2020) Annette M. Molinaro et al. JAMA Oncology
- cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading
- (2020) David N. Louis et al. BRAIN PATHOLOGY
- Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification
- (2020) Robert H. Press et al. CANCER
- GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
- (2020) Meredith Becker Buxton et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms and therapeutic implications of hypermutation in gliomas
- (2020) Mehdi Touat et al. NATURE
- Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
- (2020) Patrick Y Wen et al. NEURO-ONCOLOGY
- A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
- (2020) Carmen Balana et al. NEURO-ONCOLOGY
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- (2020) David A. Reardon et al. JAMA Oncology
- Infratentorial IDH-mutant astrocytoma is a distinct subtype
- (2020) Rouzbeh Banan et al. ACTA NEUROPATHOLOGICA
- Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system
- (2020) Emilie Le Rhun et al. CANCER LETTERS
- How did lomustine become standard of care in recurrent glioblastoma?
- (2020) Michael Weller et al. CANCER TREATMENT REVIEWS
- Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma
- (2020) Erica H. Bell et al. JOURNAL OF CLINICAL ONCOLOGY
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
- (2019) Ulrich Herrlinger et al. LANCET
- Radiology reporting of low-grade glioma growth underestimates tumor expansion
- (2019) Chloe Gui et al. ACTA NEUROCHIRURGICA
- Frame-based stereotactic biopsy of deep-seated and midline structures in 511 procedures: feasibility, risk profile, and diagnostic yield
- (2019) Christina A. Hamisch et al. ACTA NEUROCHIRURGICA
- Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions
- (2019) Damian Stichel et al. ACTA NEUROPATHOLOGICA
- PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas
- (2019) R Appay et al. NEURO-ONCOLOGY
- Carbon ion radiotherapy in the treatment of gliomas: a review
- (2019) Timothy D. Malouff et al. JOURNAL OF NEURO-ONCOLOGY
- Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016
- (2019) Roberta Rudà et al. JOURNAL OF NEURO-ONCOLOGY
- Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria
- (2019) C Mircea S Tesileanu et al. NEURO-ONCOLOGY
- ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION
- (2019) Martin van den Bent et al. NEURO-ONCOLOGY
- ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA
- (2019) Christina Tsien et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016
- (2019) Quinn T Ostrom et al. NEURO-ONCOLOGY
- Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities
- (2019) Annekathrin Reinhardt et al. Acta Neuropathologica Communications
- Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy for Epilepsy: Systematic Review of Technique, Indications, and Outcomes
- (2019) Brett E Youngerman et al. NEUROSURGERY
- Novel, improved grading system(s) for IDH-mutant astrocytic gliomas
- (2018) Mitsuaki Shirahata et al. ACTA NEUROPATHOLOGICA
- Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
- (2018) H -G Wirsching et al. ANNALS OF ONCOLOGY
- Where does O6 -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?
- (2018) Michael Weller CANCER
- Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
- (2018) Sherise D Ferguson et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- DNA methylation-based classification of central nervous system tumours
- (2018) David Capper et al. NATURE
- Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma
- (2018) Martin J. B. Taphoorn et al. JAMA Oncology
- cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
- (2018) Daniel J. Brat et al. ACTA NEUROPATHOLOGICA
- Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
- (2018) Martin J van den Bent et al. LANCET ONCOLOGY
- Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas
- (2018) Anastasia Zikou et al. Contrast Media & Molecular Imaging
- BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
- (2018) Thomas Kaley et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
- (2017) Roger Stupp et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry
- (2017) Birthe Krogh Rasmussen et al. JOURNAL OF NEURO-ONCOLOGY
- Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
- (2017) Martin J van den Bent et al. LANCET
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
- (2017) Michael Weller et al. LANCET ONCOLOGY
- European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma
- (2017) Andrea Pace et al. LANCET ONCOLOGY
- The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria
- (2017) Lakshmi Nayak et al. NEURO-ONCOLOGY
- The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis
- (2017) Maarten M J Wijnenga et al. NEURO-ONCOLOGY
- Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
- (2017) Benjamin M. Ellingson et al. Neurotherapeutics
- Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
- (2017) James R. Perry et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lomustine and Bevacizumab in Progressive Glioblastoma
- (2017) Wolfgang Wick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Corticosteroids compromise survival in glioblastoma
- (2016) Kenneth L. Pitter et al. BRAIN
- Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel
- (2016) Angela Zacher et al. BRAIN PATHOLOGY
- Surgeon volume and 30 day mortality for brain tumours in England
- (2016) Matt Williams et al. BRITISH JOURNAL OF CANCER
- Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors
- (2016) Pierre Bady et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
- (2016) Brigitta G Baumert et al. LANCET ONCOLOGY
- Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
- (2016) Nathalie L. Albert et al. NEURO-ONCOLOGY
- TTFields: where does all the skepticism come from?
- (2016) Wolfgang Wick NEURO-ONCOLOGY
- The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma
- (2016) F. Bernard-Arnoux et al. NEURO-ONCOLOGY
- Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial
- (2016) Bogdana Suchorska et al. NEURO-ONCOLOGY
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
- (2016) Jan C. Buckner et al. NEW ENGLAND JOURNAL OF MEDICINE
- ESTRO-ACROP guideline “target delineation of glioblastomas”
- (2016) Maximilian Niyazi et al. RADIOTHERAPY AND ONCOLOGY
- Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma
- (2016) S. B. Harrabi et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Patterns and Time Dependence of Unspecific Enhancement in Postoperative Magnetic Resonance Imaging After Glioblastoma Resection
- (2016) Stefanie Bette et al. World Neurosurgery
- Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets
- (2015) Felix Sahm et al. ACTA NEUROPATHOLOGICA
- Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
- (2015) David E. Reuss et al. ACTA NEUROPATHOLOGICA
- MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
- (2015) M. Weller et al. CLINICAL CANCER RESEARCH
- International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme
- (2015) Wilson Roa et al. JOURNAL OF CLINICAL ONCOLOGY
- NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI)
- (2015) Benjamin Ellingson et al. NEURO-ONCOLOGY
- Primo non nocere or maximum survival in grade 2 gliomas? A medical ethical question
- (2014) Jannick Brennum et al. ACTA NEUROCHIRURGICA
- Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients
- (2014) Sabina Eigenbrod et al. ACTA NEUROCHIRURGICA
- Presenting symptoms of glioma in adults
- (2014) J. P. Posti et al. ACTA NEUROLOGICA SCANDINAVICA
- The role of radiotherapy in the management of progressive glioblastoma
- (2014) Samuel Ryu et al. JOURNAL OF NEURO-ONCOLOGY
- Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma
- (2014) Matthew M. Grabowski et al. JOURNAL OF NEUROSURGERY
- Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence
- (2014) A. Radbruch et al. NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors
- (2013) Esther J. J. Habets et al. JOURNAL OF NEURO-ONCOLOGY
- IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
- (2013) Jason Beiko et al. NEURO-ONCOLOGY
- Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
- (2013) W. Wick et al. NEUROLOGY
- Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma
- (2012) Dominik Sturm et al. CANCER CELL
- NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
- (2012) Roger Stupp et al. EUROPEAN JOURNAL OF CANCER
- Impact of Intraoperative Stimulation Brain Mapping on Glioma Surgery Outcome: A Meta-Analysis
- (2012) Philip C. De Witt Hamer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
- (2012) Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
- (2012) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- The Risk of Getting Worse: Surgically Acquired Deficits, Perioperative Complications, and Functional Outcomes After Primary Resection of Glioblastoma
- (2012) Sasha Gulati et al. World Neurosurgery
- Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
- (2011) MJ van den Bent et al. LANCET ONCOLOGY
- Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
- (2010) Michael Brada et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
- (2010) James R. Perry et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
- (2009) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now